STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Leerink Therapeutics Forum.
STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Leerink Therapeutics Forum.
Location: Boston Harbor Hotel, Boston, Mass.
Format: 1×1 meetings
Date: Tuesday, July 14, 2026
Participant: Ahmed Mousa, CEO
STOCKHOLM, SE / ACCESS Newswire / May 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a…
STOCKHOLM, SE AND CAMBRIDGE, MA / ACCESS Newswire / July 1, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq…
Proposed dual listing expected to broaden access to US investors as buloxibutid advances toward its Phase 2b readout in IPF, with…
STOCKHOLM, SE / ACCESS Newswire / July 6, 2026 / Vicore Pharma Holding (STO:VICO) - Dr. Slack brings over 20 years' experience in…
Citi Appointed as Depositary Bank for Vicore Pharma Holding AB’s ADR Program
Viking Therapeutics to Participate at Upcoming Investor Conferences
